An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
SOL Global Announces Closing of Settlement with 1235 Fund LP and the Completion of its Normal Course Issuer Bid for Purchase of 5% of Company’s Common Shares
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Negative)
Tags
Issued and outstanding common shares now reduced to 52,018,533
TORONTO--(BUSINESS WIRE)--
SOL Global Investments Corp. (“SOL Global” or the "Company”) (CSE: SOL) (OTCQB: SOLCF) (Frankfurt: 9SB) is pleased to announce the closing of its previously disclosed settlement of litigation with 1235 Fund LP (“1235”) relating to a senior, secured non-convertible debenture issued and sold to 1235 in the principal amount of CAD$50 million (the “Debenture”). Pursuant to the settlement, the Company paid CAD$120 million (which is CAD $68.5 million above the Debenture’s principal and accrued interest) to 1235 (the “Settlement Payment”). As previously disclosed, SOL Global had commenced legal proceedings in New York against 1235 and another entity, and 1235 had commenced legal proceedings against SOL Global and others in Ontario. Both legal proceedings concerned the interpretation of the Debenture and related agreements and the rights of the parties under these agreements. With the Settlement Payment having been completed, both legal proceedings will now be dismissed without costs.
In addition, the Company is pleased to announce the completion of its normal course issuer (“NCIB”) for the purchase of 2,737,805 common shares in the capital of the Company (the “Common Shares”), representing approximately 5% of its issued and outstanding Common Shares at the time of the commencement of the NCIB. The Common Shares were purchased through the facilities of the Canadian Securities Exchange at an average purchase price of $4.1466 per Common Share.
Clarus Securities Inc. acted as the Company's broker to conduct the NCIB on the Company's behalf. All of the Common Shares purchased by the Company under the NCIB have been cancelled. The Company's new number of issued and outstanding Common Shares is 52,018,533.
About SOL Global Investments Corp.:
SOL Global is a diversified investment and private equity holding company engaged in the small and mid-cap sectors. The Company’s investment partnerships range from minority positions to large strategic holdings with active advisory mandates. The Company’s six primary business segments include Retail (QSR & Hospitality), Agriculture including Cannabis, Technology (with a focus on Clean-Tech and EVs), Esports and Gaming, Cryptocurrency, and New Age Wellness.
scythian is a pharmaceutical development company currently undertaking pre-clinical testing at the university of miami on a combination drug therapy for the treatment of traumatic brain injury ("tbi") and concussion. tbi happens when there is a major impact to the head or subjected to accelerative forces. it frequently results in both initial damage from the impact itself and significant subsequent damage from inflammation and the body's own immune response. a significant amount of brain injury occurs from the inflammatory and immune response. scythian’s pharmaceutical approach aims to reduce both the inflammation and the immune response by using a combination of two drugs as the acute emergency room or post injury treatment. a broad based u.s. provisional patent application has been filed utilizing drug combinations which affect the endocannabinoid pathway to treat concussions. scythian's second business line is its application to become a licensed producer of medical marijuana in can